Desmond O'Neill

Desmond O'Neill

Auto-generated profile, based on publicly available information

Desmond O'Neill

Trinity College Dublin

Research Focus & Metrics

Academic Career Length

76Years (1951-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2011 in BMJ
Verified
Journal Article
Open access
PDF file
GEGraham Ellis
Graham Ellis
MWM. A. Whitehead
M. A. Whitehead
DRDavid Robinson
David Robinson
DODesmond O’neill
Desmond O’neill
PLPeter Langhorne
Peter Langhorne
Objective To evaluate the effectiveness of comprehensive geriatric assessment in hospital for older adults admitted as an emergency. Search strategy We searched the EPOC Register, Cochrane’s Controlled Trials Register, the Database of Abstracts of Reviews of Effects (DARE), Medline, Embase, CINAHL, AARP Ageline, and handsearched high yield journals. Selection criteria Randomised controlled trials of comprehensive geriatric assessment (whether by mobile teams or in designated wards) compared with usual care. Comprehensive geriatric assessment is a multidimensional interdisciplinary diagnostic process used to determine the medical, psychological, and functional capabilities of a frail elderly person to develop a coordinated and integrated plan for treatment and long term follow-up. Data collection and analysis Three independent reviewers assessed eligibility and trial quality and extracted published data. Two additional reviewers moderated. Results Twenty two trials evaluating 10 315 participants in six countries were identified. For the primary outcome “living at home,” patients who underwent comprehensive geriatric assessment were more likely to be alive and in their own homes at the end of scheduled follow-up (odds ratio 1.16 (95% confidence interval 1.05 to 1.28; P=0.003; number needed to treat 33) at a median follow-up of 12 months versus 1.25 (1.11 to 1.42; P<0.001; number needed to treat 17) at a median follow-up of six months) compared with patients who received general medical care. In addition, patients were less likely to be living in residential care (0.78, 0.69 to 0.88; P<0.001). Subgroup interaction suggested differences between the subgroups “wards” and “teams” in favour of wards. Patients were also less likely to die or experience deterioration (0.76, 0.64 to 0.90; P=0.001) and were more likely to experience improved cognition (standardised mean difference 0.08, 0.01 to 0.15; P=0.02) in the comprehensive geriatric assessment group. Conclusions Comprehensive geriatric assessment increases patients’ likelihood of being alive and in their own homes after an emergency admission to hospital. This seems to be especially true for trials of wards designated for comprehensive geriatric assessment and is associated with a potential cost reduction compared with general medical care.

12 September 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
GEGraham Ellis
Graham Ellis
MGMike Gardner
Mike Gardner
ATApostolos Tsiachristas
Apostolos Tsiachristas
PLPeter Langhorne
Peter Langhorne
OBOrlaith Burke
Orlaith Burke
SSSasha Shepperd
Sasha Shepperd

1 June 2016 in Clinical Medicine
Verified
Journal Article
Open access
PDF file
RBRobert Briggs
Robert Briggs
SKSean P Kennelly
Sean P Kennelly
DODesmond O’nEill
Desmond O’nEill
Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer’s disease (AD) and these act to control symptoms rather than alter the course of the disease. Studies of potential disease-modifying therapy have generally been undertaken in patients with clinically detectable disease, yet evidence suggests that the pathological changes associated with AD begin several years before this. It is possible that pharmacological therapy may be beneficial in this pre-clinical stage before the neurodegenerative process is established. Techniques providing earlier diagnosis, such as cerebrospinal fluid biomarkers and amyloid positron emission tomography neuroimaging, are key to testing this theory in clinical trials. Recent results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution. Such medicines could potentially delay the onset of dementia and would therefore markedly reduce its prevalence. However, we currently remain a good distance away from clinically available disease-modifying therapy.

1 January 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
DDDominique Deplanque
Dominique Deplanque
CMCharles B L M Majoie
Charles B L M Majoie
BMBijoy K Menon
Bijoy K Menon
YNYassi Nawaf
Yassi Nawaf
GSGagan Sharma
Gagan Sharma
JCJames Cunningham
James Cunningham

6 July 2011
Verified
Reference Entry
Closed access
PDF file
GEGraham Ellis
Graham Ellis
MWMartin A Whitehead
Martin A Whitehead
DODesmond O'Neill
Desmond O'Neill
PLPeter Langhorne
Peter Langhorne
DRDavid Robinson
David Robinson

1 October 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
ARAránzazu Román-San-Miguel
Aránzazu Román-San-Miguel
BMBijoy K Menon
Bijoy K Menon
JBJordi Blasco
Jordi Blasco
MHMaría Hernández-Pérez
María Hernández-Pérez
ADAntoni Dávalos
Antoni Dávalos
JCJames Cunningham
James Cunningham